Inventiva S.A (PA:IVA) — Market Cap & Net Worth
Market Cap & Net Worth: Inventiva S.A (IVA)
Inventiva S.A (PA:IVA) has a market capitalization of $833.89 Million (€713.27 Million) as of September 16, 2026. Listed on the PA stock exchange, this France-based company holds position #9719 globally and #152 in its home market, demonstrating a -14.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inventiva S.A's stock price €3.44 by its total outstanding shares 207647924 (207.65 Million). Also see IVA asset base for a full breakdown of the balance sheet.
Inventiva S.A Market Cap History: 2017 to 2026
Inventiva S.A's market capitalization history from 2017 to 2026. Data shows change from $1.20 Billion to $833.89 Million (-9.11% CAGR). Also see Inventiva S.A cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Inventiva S.A is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$230.53 Billion | 0.36% | #55 of 119 |
|
CAC Small90
CACS
|
$36.86 Billion | 2.26% | #12 of 64 |
|
CAC All-Tradable
CACT
|
$2.85 Trillion | 0.03% | #114 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.85 Trillion | 0.03% | #114 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.85 Trillion | 0.03% | #114 of 179 |
|
CAC Health Care
FRHC
|
$241.84 Billion | 0.34% | #12 of 36 |
Weight: Inventiva S.A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Inventiva S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inventiva S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Inventiva S.A stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
213.63x
Inventiva S.A's market cap is 213.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.20 Billion | $6.52 Million | -$17.23 Million | 184.28x | N/A |
| 2018 | $1.36 Billion | $3.20 Million | -$33.62 Million | 426.75x | N/A |
| 2019 | $890.94 Million | $7.00 Million | -$30.22 Million | 127.31x | N/A |
| 2020 | $2.85 Billion | $372.00K | -$31.62 Million | 7648.32x | N/A |
| 2021 | $2.85 Billion | $4.19 Million | -$49.64 Million | 679.55x | N/A |
| 2022 | $1.09 Billion | $12.18 Million | -$54.27 Million | 89.20x | N/A |
| 2023 | $994.11 Million | $17.48 Million | -$110.43 Million | 56.88x | N/A |
| 2024 | $529.22 Million | $14.72 Million | -$184.21 Million | 35.94x | N/A |
| 2025 | $957.70 Million | $4.48 Million | -$354.14 Million | 213.63x | N/A |
Competitor Companies of IVA by Market Capitalization
Companies near Inventiva S.A in the global market cap rankings as of September 16, 2026. Review tangible equity quality of Inventiva S.A to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Inventiva S.A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Inventiva S.A Historical Marketcap From 2017 to 2026
Between 2017 and today, Inventiva S.A's market cap moved from $1.20 Billion to $ 833.89 Million, with a yearly change of -9.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €833.89 Million | -12.93% |
| 2025 | €957.70 Million | +80.96% |
| 2024 | €529.22 Million | -46.76% |
| 2023 | €994.11 Million | -8.49% |
| 2022 | €1.09 Billion | -61.88% |
| 2021 | €2.85 Billion | +0.17% |
| 2020 | €2.85 Billion | +219.35% |
| 2019 | €890.94 Million | -34.70% |
| 2018 | €1.36 Billion | +13.54% |
| 2017 | €1.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Inventiva S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $833.89 Million USD |
| MoneyControl | $833.89 Million USD |
| MarketWatch | $833.89 Million USD |
| marketcap.company | $833.89 Million USD |
| Reuters | $833.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more